Adare has recently launched a new patient centric dosage solution, the Parvulet TM Technology. The Parvulet TM Technology enables a solid powder or tablet to convert to a semi-solid in the presence of water within thirty seconds. The final dosage is easily administered, as a soft food like texture, ideal for pediatric and geriatric populations (including those with dysphagia).
Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The completely encapsulated particle allows for a pleasant mouthfeel without an aftertaste. The Microcaps technology can be applied to multiple dosage forms and immediate and modified release profiles.
AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who have difficulty swallowing, pediatric, geriatric, and dysphagic patients. This technology can be combined with Microcaps® and Diffucaps® to create IR or controlled-release ODTs.
Diffucaps® Customized Release Technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This allows for easy adjustment of both dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile. Beads can have different release profiles, different active ingredients, or both—all in one product.
MMTS TM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets—a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule.
Major Markets
Adare Pharmaceuticals has four sites located in the US and Europe with over 600 employees worldwide. With our global R&D and manufacturing capabilities, in-house regulatory and clinical support, we have the expertise to take your project from formulation development through commercial scale manufacturing. Our sites are compliant with cGMP criteria and approved to handle controlled substances and solvents, and maintain excellent environmental credentials. Our in house regulatory and quality teams have a proven global track record with the FDA, AIFA in Italy, EMA in Europe and ANVISA for Brazil.
Adare Pharmaceuticals is proud to be leading partners across Branded, Specialty, Generic,Veterinarian, and OTC segments.
Services Offered
Technology Platforms:
• ODTs and Taste Masking
• Customized Drug Release
• Bioavailability Enhancement
Commercial Manufacturing Capabilities:
• Granulation and Mixing
• Fluid Bed Processing
o Wurster
o Top Spray
• Pan Coating
• Blending (Bin and Static)
• Tableting
• Capsule Filling
• Oven Drying
• Regulatory expertise for NDA filing (including 505(b)(2)) and ANDA filings
• Microencapsulation of solids and liquids
• Orally disintegrating tablets
• Dry syrup
• Minitabs
• Enzyme Formulation
• Solvent based processing
• Controlled Substances